Tigo Expands TS4-A Platform with New Add-on UL-system-certified Rapid Shutdown Solution
18.3.2020 16:00:00 EET | Business Wire | Press release
Tigo Energy, Inc.®, pioneer of the smart modular Flex MLPE, today announced a new addition to the add-on TS4 Platform - the TS4-A-S. This add-on safety solution brings the solar market’s only module-level power electronic (MLPE) multivendor UL-system-certified solution for rapid shutdown. Tigo’s safety solution complies with NEC 2014, 2017, and 2020 with more than 100 inverters for residential, commercial & industrial, and utility customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005094/en/
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by Tigo's communication accessories. Production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. Now taking orders for the TS4-A-S worldwide. (Photo: Business Wire)
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by the Tigo Access Point (TAP) and the Cloud Connect Advanced (CCA). DC production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. This TS4-A-S launch accompanies the recently announced TS4-A-M (Monitoring Add-on) launch earlier this month. These units complete Tigo’s transition from the legacy TS4-R retrofit platform to the TS4-A add-on platform with mechanical upgrades, UHD-Core technology, expanded specifications to support PV modules up to 500W. To learn more, join Tigo's free online "Rapid Shutdown featuring the TS4-A-S & NEC 2020" webinar on Thursday, March 26th at 10am PT.
The highlights of the new TS4-A-S (Safety Add-on) with rapid shutdown include:
- Comply with NEC 2014, 2017, 2020 rapid shutdown requirements
- Choose compatibility from more than 100 UL-system-certified inverters
- Choose compatibility from any module up to 500W
- Manual or automatic shutdown in event of AC grid loss
- Automatic email or SMS alerts about faults or operational issues
- Protect PV system assets with full visibility of performance
- Lower O&M costs when identifying specific module problems
- Utilize module manufacturer warranties when tracking module failures
“Only inverters and rapid shutdown devices that have been UL-certified as a system are certified as safe. There’s one multivendor solution for residential C&I – and that’s Tigo,” says Danny Eizips, VP of Hardware Engineering at Tigo. “Others might not meet mandatory safety requirements, and therefore, cannot be trusted as safe when installed together in one PV system. We're working diligently to educate our partners and customers worldwide to know the difference for the safest solar experience.”
Tigo is now taking orders for the TS4-A-S worldwide. The last inventory of legacy TS4-R-S units may be shipped per the discretion of Tigo and Tigo’s distribution partners as the new TS4-A-S shipments are prepared. Both units are fully backward compatible. For price and delivery, consult your preferred solar distributor, call Tigo at +1.408.402.0802, email sales@tigoenergy.com, or visit www.tigoenergy.com.
About Tigo Energy, Inc.
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005094/en/
Contact information
Tiffany Douglass
408.402.0802 x 430
marketing@tigoenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom